Abstract
This paper discusses the basic principles of drug/P-glycoprotein (P-gp) interaction, focusing on the methodology and design of positron emission tomography (PET) studies investigating P-gp function. The requirements of a good PET P-gp radiotracer are also evaluated. (R)-[11C]verapamil is used as an example, as this drug is the most common tracer for P-gp studies, but [11C]loperamide, [11C]desmethyl-loperamide and other compounds are also mentioned. The article also discusses the various study designs that can be used for PET drug disposition studies, such as administration of the inhibitor before or after the radiolabeled drug (tracer) and the use of bolus injections or infusions. Concepts such as the unbound partition coefficient (Kp,uu) and the volume of distribution of unbound drug in brain (Vu,brain), which are not easily measured directly with PET, can be used to describe the impact of protein binding and non-specific binding on drug distribution in brain tissue. It is concluded that new imaging probes will be required if the role of PET in studies of the interactions of drugs with efflux transporters is to expand.
Keywords: P-glycoprotein, PET, study design, pharmacokinetics, blood-brain barrier, active transport, efflux pumps, drug interactions
Current Topics in Medicinal Chemistry
Title: Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs
Volume: 10 Issue: 17
Author(s): Stina Syvanen and Margareta Hammarlund-Udenaes
Affiliation:
Keywords: P-glycoprotein, PET, study design, pharmacokinetics, blood-brain barrier, active transport, efflux pumps, drug interactions
Abstract: This paper discusses the basic principles of drug/P-glycoprotein (P-gp) interaction, focusing on the methodology and design of positron emission tomography (PET) studies investigating P-gp function. The requirements of a good PET P-gp radiotracer are also evaluated. (R)-[11C]verapamil is used as an example, as this drug is the most common tracer for P-gp studies, but [11C]loperamide, [11C]desmethyl-loperamide and other compounds are also mentioned. The article also discusses the various study designs that can be used for PET drug disposition studies, such as administration of the inhibitor before or after the radiolabeled drug (tracer) and the use of bolus injections or infusions. Concepts such as the unbound partition coefficient (Kp,uu) and the volume of distribution of unbound drug in brain (Vu,brain), which are not easily measured directly with PET, can be used to describe the impact of protein binding and non-specific binding on drug distribution in brain tissue. It is concluded that new imaging probes will be required if the role of PET in studies of the interactions of drugs with efflux transporters is to expand.
Export Options
About this article
Cite this article as:
Syvanen Stina and Hammarlund-Udenaes Margareta, Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs, Current Topics in Medicinal Chemistry 2010; 10 (17) . https://dx.doi.org/10.2174/156802610792927997
DOI https://dx.doi.org/10.2174/156802610792927997 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson’s Disease
Current Drug Targets Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors
Current Neuropharmacology 3D Printing Technology in Pharmaceutical Manufacturing and Drug Delivery Application
Current Pharmaceutical Design An Introduction to Molecular Modeling of G-Protein Coupled Receptors
Current Computer-Aided Drug Design Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Current Pharmaceutical Design Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Medication-precipitated Seizure in Psychiatric Patients: Typical vs. Atypical Antipsychotics
Current Psychopharmacology Drug Treatment of Epilepsy: From Serendipitous Discovery to Evolutionary Mechanisms
Current Medicinal Chemistry Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Synthesis, Anticonvulsant and Binding Interaction Study of Novel Piperamides with Bovine Serum Albumin by Fluorescence Spectroscopy
Central Nervous System Agents in Medicinal Chemistry Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Current Pharmaceutical Design Molecular Docking, Synthesis and CNS Activity of Some Novel 1, 4-Benzodiazepine Derivatives
Letters in Drug Design & Discovery Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Implications of Prion Protein Biology
Current Neurovascular Research Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death
Current Neuropharmacology Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy